ZUMA-3 investigator, Bijal Shah presents interim phase I data on KTE-X19 (NCT02614066). The need for this investigational anti-CD19 CAR T cell therapy in adult patients with relapsed/refractory acute lymphoblastic leukemia and its mechanism of action are discussed alongside the results of this study.
1. What are the major unmet needs in the treatment of adults with relapsed or refractory acute lymphoblastic leukaemia? (0:04)
2. Could you tell us a little about KTE-X19 and its mechanism of action? (1:08)
3. What were the key inclusion and exclusion criteria of the ZUMA-3 study? (1:58)
4. What were the efficacy and safety findings of the interim analysis of phase 1 of ZUMA-3? (3:08)
5. Please could you tell us how you managed neurotoxicity in this study? (3:54)
Speaker disclosure: Bijal Shah has acted as a consultant for Adaptive Biotechnologies, received honoraria from Pharmacyclics/Janssen and research funding from Incyte and Jazz Pharmaceuticals.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Leukaemia
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia – results from a phase II pivotal clinical trial
Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses the results from a recent clinical trial that were presented at ASH 2022. Abstract 2757: ‘Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial‘ Disclosures: Jorge Cortes is a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!